281 related articles for article (PubMed ID: 24580843)
1. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.
Jin YP; Valenzuela NM; Ziegler ME; Rozengurt E; Reed EF
Am J Transplant; 2014 Apr; 14(4):806-19. PubMed ID: 24580843
[TBL] [Abstract][Full Text] [Related]
2. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway.
Jindra PT; Jin YP; Rozengurt E; Reed EF
J Immunol; 2008 Feb; 180(4):2357-66. PubMed ID: 18250445
[TBL] [Abstract][Full Text] [Related]
3. HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection.
Jin YP; Valenzuela NM; Zhang X; Rozengurt E; Reed EF
J Immunol; 2018 Apr; 200(7):2372-2390. PubMed ID: 29475988
[TBL] [Abstract][Full Text] [Related]
4. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
Witzig TE; Reeder C; Han JJ; LaPlant B; Stenson M; Tun HW; Macon W; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic S; Nowakowski GS; Gupta M
Blood; 2015 Jul; 126(3):328-35. PubMed ID: 25921059
[TBL] [Abstract][Full Text] [Related]
5. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
7. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
8. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
Martin EC; Rhodes LV; Elliott S; Krebs AE; Nephew KP; Flemington EK; Collins-Burow BM; Burow ME
Mol Cancer; 2014 Oct; 13():229. PubMed ID: 25283550
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
[TBL] [Abstract][Full Text] [Related]
10. HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2+ in human aortic endothelial cells.
Ziegler ME; Jin YP; Young SH; Rozengurt E; Reed EF
Am J Physiol Cell Physiol; 2012 Oct; 303(8):C872-82. PubMed ID: 22914643
[TBL] [Abstract][Full Text] [Related]
11. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
[TBL] [Abstract][Full Text] [Related]
12. Inorganic polyphosphate elicits pro-inflammatory responses through activation of the mammalian target of rapamycin complexes 1 and 2 in vascular endothelial cells.
Hassanian SM; Dinarvand P; Smith SA; Rezaie AR
J Thromb Haemost; 2015 May; 13(5):860-71. PubMed ID: 25776944
[TBL] [Abstract][Full Text] [Related]
13. Cellular and molecular effects of the mTOR inhibitor everolimus.
Saran U; Foti M; Dufour JF
Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617
[TBL] [Abstract][Full Text] [Related]
14. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells.
Jin YP; Fishbein MC; Said JW; Jindra PT; Rajalingam R; Rozengurt E; Reed EF
Hum Immunol; 2004 Apr; 65(4):291-302. PubMed ID: 15120184
[TBL] [Abstract][Full Text] [Related]
15. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
Gupta M; Ansell SM; Novak AJ; Kumar S; Kaufmann SH; Witzig TE
Blood; 2009 Oct; 114(14):2926-35. PubMed ID: 19641186
[TBL] [Abstract][Full Text] [Related]
17. Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection.
Salehi S; Sosa RA; Jin YP; Kageyama S; Fishbein MC; Rozengurt E; Kupiec-Weglinski JW; Reed EF
Am J Transplant; 2018 May; 18(5):1096-1109. PubMed ID: 29045076
[TBL] [Abstract][Full Text] [Related]
18. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.
Liu L; Luo Y; Chen L; Shen T; Xu B; Chen W; Zhou H; Han X; Huang S
J Biol Chem; 2010 Dec; 285(49):38362-73. PubMed ID: 20937815
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S
Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
